Clarke, Stuart C. (2006) Control of pneumococcal disease in the United Kingdom – the start of a new era. Journal of Medical Microbiology, 55 (8), 975-80. (doi:10.1099/jmm.0.46579-0).
Abstract
In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed for use in
infants and young children in the USA. The subsequent introduction of the vaccine into the
childhood immunization schedule in that country led to a significant decrease in pneumococcal
disease. The vaccine is effective against invasive and non-invasive pneumococcal infection, can be
used in young children as well as adults and, like all conjugate vaccines, provides long-lasting
immunity. Moreover, it reduces the incidence of antibiotic resistance because a number of
resistant serotypes are targeted by the vaccine. Prevnar, also known as Prevenar, has since been
licensed in numerous countries, including the UK.On 8 February 2006, the Departments of Health in
England, Scotland and Wales announced the inclusion of Prevenar in the childhood immunization
schedule. This announcement has important implications for pneumococcal infection, disease
surveillance and immunization policy in the UK.
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.